Medherant is developing TEPI Patch® technology for transdermal drug delivery, specifically targeting prescription and OTC medications for women's health, pain management, and central nervous system disorders. This technology enhances patient compliance and comfort by providing a convenient, non-invasive alternative to traditional oral medications.
Funding
$3.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many medications, especially those for women's health, pain management, and central nervous system disorders, are administered orally, which can lead to variable absorption rates, systemic side effects, and reduced patient compliance. Traditional transdermal patches often have limitations in drug loading and delivery rates, hindering their effectiveness for certain medications.
Solution
Medherant is developing TEPI Patch® technology, a novel approach to transdermal drug delivery that aims to improve patient outcomes and adherence. TEPI Patch® technology allows for higher drug loading and controlled release of medications directly through the skin, bypassing the gastrointestinal tract and potentially reducing systemic side effects. This technology offers a convenient, non-invasive alternative to oral medications, potentially improving patient comfort and adherence, particularly for women's health, pain management, and central nervous system disorders.
Target Audience
The primary target audience includes patients requiring prescription and over-the-counter medications for women's health issues, pain management, and central nervous system disorders, as well as healthcare providers seeking improved drug delivery methods.
Features
- Enhanced drug loading capacity compared to conventional transdermal patches
- Controlled and sustained drug release profiles for consistent therapeutic effects
- Improved skin adhesion for reliable delivery
- Potential for reduced systemic side effects due to targeted delivery
- Non-invasive and convenient application for improved patient compliance